In addition to Company’s other reporting and disclosure obligations contained in this Agreement, Company shall, and shall cause all other Responsible Parties to, upon Bain’s reasonable request, promptly prepare and provide Bain with reasonable notice and information regarding each of the following matters relating to the Product and to promptly respond to Bain’s reasonable inquiries with respect thereto and promptly provide, upon Bain’s reasonable request, information and documents related to each of the following matters, in each case, to the extent relating to the Development and Commercialization of the Product in the Territory:

Information; Additional Rights. Subject to the applicable limitations set forth in this Agreement, until the Closing or earlier termination of this Agreement, allow the Buyer to:

Information Rights. At all times (if any) after the Loan Agreement has been terminated and prior to the earlier to occur of # the date on which all shares of Common Stock issued on exercise of this Warrant have been sold, or # the expiration or earlier termination of this Warrant, when the Company shall not be required to file reports pursuant to Section 13 or 15(d) of the Exchange Act or shall not have timely filed all such required reports, the Warrantholder shall be entitled to the information rights contained in [Section 7.1(c)] of the Loan Agreement, and in any such event # [Section 7.1(c)] of the Loan Agreement is hereby incorporated into this Agreement by this reference as though fully set forth herein and # any such information shall be subject to the confidentiality obligations of [Section 11.13] of the Loan Agreement, which is hereby incorporated into this Agreement by this reference as though fully set forth herein and such confidentiality obligations shall survive for three years from the expiration of this Warrant.

Shareholder Information Rights. Without limiting the generality of the information and inspection rights of Article III of the Investor Rights Agreement, the Company shall, and shall cause each of its Subsidiaries to, promptly, upon reasonable request, # make available to Sumitovant and its Representatives such information, documents and other materials, whether current, historical or prospective, relating to the business of the Company or any of its Subsidiaries and in its possession and control (and subject to any Third Party confidentiality and use obligations or limitations) as Sumitovant may from time to time reasonably request, including, for the avoidance of doubt, clinical data and other regulatory information pertaining to the Company or any of its Subsidiaries, subject at all times to applicable law regarding the disclosure of such information; and # give Sumitovant and its Subsidiaries the reasonable opportunity to discuss any matters with the Company’s and its Subsidiaries’ senior management, in the case of each of clauses (A) and (B) in connection with any proper purpose. For the avoidance of doubt, proper purpose includes disclosure to Sumitovant of any such information, data, documents or other materials for its own internal research purposes, including but not limited to, for purposes of analyzing, and/or deriving learnings from, clinical data provided by the Company to Sumitovant hereunder; provided that, in no event does the provision of information hereunder grant Sumitovant any right # to disclose any such information to any Affiliate except that Sumitovant may disclose such information to Sumitomo on an as-needed basis subject to its obligations and any restrictions hereunder, # to use any such information in any manner deemed in good faith by Sumitovant to be detrimental to the Company or its minority shareholders, or # or to grant any other rights or licenses under or to any of the Company’s intellectual property, compounds, products or programs.

Information Rights. So long as Holder holds this Warrant and/or any of the Shares, the Company shall deliver to Holder # promptly, copies of all notices or other written communications to which Holder would be entitled if it held Shares as to which this Warrant was then exercisable, and # within 45 days after the end of each of the first three quarters of each fiscal year, the Company’s quarterly, unaudited financial statements and within 90 days after the end of each fiscal year, the Company’s annual, audited financial statements; provided, however, that with regard to annual meeting proxy statements and [clause (ii) of this Section 3.5], it is understood and agreed that there shall be no such delivery requirement with respect to any such proxy statements or financial statements if such documents are available on EDGAR.

Information Rights. So long as the Note remains outstanding and until such time as the Purchasers no longer is the beneficial owner of at least ten percent (10%) of the outstanding Common Stock, on a fully diluted basis, the Company shall provide the Purchasers with # monthly financial reports including A/R and A/P statements within 30 days of each month end, with such reports to also include comparisons of budgeted to actual operations # quarterly financial reports within 30 days of each quarter end, with such reports to include comparisons of budgeted to actual operations, # yearly financial reports within 60 days of each year end, with such reports to include comparisons of budgeted to actual operations and # audited financials within 120 days of each year end. Upon the request of the Purchasers, the Company shall share with the Purchasers status updates on manufacturing and capex, shipment of products, sales pipeline, board decisions and relevant regulatory and licensing developments. The Company shall use best efforts to provide accurate quarterly and yearly reports, subject to adjustments recommended by the Company’s auditors.

Information Rights. So long as Medytox owns ​ or more of the issued and outstanding Common Stock of AEON, on a fully diluted basis, AEON will furnish to Medytox:

Information Rights. From the Effective Date through the final Measurement Period unless Buyer’s obligation to make Contingent Payments is terminated pursuant to the terms of this Agreement, Buyer shall provide, or cause the Company to provide, to Seller the following:

Until Lilly no longer holds Shares representing beneficial ownership of at least five percent (5%) of the outstanding Common Stock, Lilly shall be entitled to consult with Precision’s Chief Executive Officer, who shall make himself or herself available quarterly on a reasonable basis and who shall respond to the reasonable information and other requests made by Lilly on a quarterly basis with respect to Precision’s business and financial matters.

General Information Rights. With respect to each of the [[Merus:Organization]] Prosecuted Patents and the Lilly Prosecuted Patents, the Prosecuting Party shall # keep the other Party (through the Patent Working Group) reasonably informed of the status of any applicable Patent or application, including by promptly providing the Patent Working Group with all material correspondence received from any Patent authority in connection therewith (including with respect to any office actions); # promptly ​, provided that, subject to [Section 9.2.3(b)] and without limiting [Section 9.2.4] with respect to ​, the Parties shall discuss such Prosecution and Maintenance only with respect to claims that specifically relate to any Collaboration Compound, Monospecific Compound, Modified Compound or Product, # ​ shall discuss such Prosecution and Maintenance only with respect to claims that ​ # all decisions relating to any ​; and # all decisions relating to any ​: # Lilly shall have final-decision making authority in respect thereto solely with respect to ​; and # [[Merus:Organization]] shall otherwise have final-decision making authority in respect to all ​; provided that [[Merus:Organization]] shall not exercise such final-decision making authority in a manner reasonably likely to ​.